1. Home
  2. Companies
  3. PTX
  4. Material Events

Prescient Therapeutics (ASX:PTX) — Material Events

ASX:PTX · 10 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 9 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
9
Prescient Therapeutics Advances PTX-100 with EMA Orphan Drug Status and Global Trial ExpansionMedium
Prescient Therapeutics secures EMA orphan drug status for PTX-100, advances Phase 2a CTCL trial with global site expansion
30 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·85
Prescient Secures EMA Orphan Drug Status for PTX-100 in CTCLMedium
Prescient Therapeutics secures EMA Orphan Drug Designation for PTX-100 in CTCL
19 Nov 2025 ·Regulatory Announcement ·85
Prescient Therapeutics Advances PTX-100 Phase 2a Trial, Reduces Loss by 4.4%, Raises $9.8MMedium
Prescient Therapeutics advances PTX-100 Phase 2a trial, reduces loss by 4.4%, raises $9.8M
21 Aug 2026 ·Preliminary Final Report and Annual Report ·85
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.